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Abstract
Background: Childhood immune thrombocytopenia (ITP) is an autoimmune bleeding 
disorder. The prognosis (transient, persistent, or chronic ITP) remains difficult to pre-
dict. The morbidity is most pronounced in children with persistent and chronic ITP. 
Clinical characteristics are associated with ITP outcomes, but there are no validated 
multivariate prediction models.
Objective: Development and external validatation of the Childhood ITP Recovery 
Score to predict transient versus persistent ITP in children with newly diagnosed ITP.
Methods: Patients with a diagnosis platelet count ≤ 20 × 109/L and age below 16 years 
were included from two prospective multicenter studies (NOPHO ITP study, N = 377 
[development cohort]; TIKI trial, N = 194 [external validation]). The primary outcome 
was transient ITP (complete recovery with platelets ≥100 × 109/L 3 months after 
diagnosis) versus persistent ITP. Age, sex, mucosal bleeding, preceding infection/vac-
cination, insidious onset, and diagnosis platelet count were used as predictors.
Results: In external validation, the score predicted transient versus persistent ITP at 
3 months follow-up with an area under the receiver operating characteristic curve of 
0.71. In patients predicted to have a high chance of recovery, we observed 85%, 90%, 
and 95% recovered 3, 6, and 12 months after the diagnosis. For patients predicted to 
have a low chance of recovery, this was 32%, 46%, and 71%. The score also predicted 
cessation of bleeding symptoms and the response to intravenous immunoglobulins (IVIg).
Conclusion: The Childhood ITP Recovery Score predicts prognosis and may be use-
ful to individualize clinical management. In future research, the additional predic-
tive value of biomarkers can be compared to this score. A risk calculator is available 
(http://www.itpre cover yscore.org).
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1  | INTRODUC TION
Childhood immune thrombocytopenia (ITP) is an acquired auto-
immune bleeding disease characterized by low platelet counts 
(≤100 × 109/L).1-3 The yearly incidence is 2 to 6 per 100 000 chil-
dren.4 Most children with newly diagnosed ITP have self-limiting 
disease courses and recover spontaneously, yet 40% of children ex-
hibit thrombocytopenia and bleeding beyond 3 months (persistent 
ITP), and 10% to 20% percent 1 year after the diagnosis (chronic 
ITP).5-7 The morbidity of childhood ITP is most significant among the 
children with persistent and chronic thrombocytopenia.8,9 To pre-
dict such persistent and chronic ITP disease courses, a systematic 
review and meta-analysis identified from the literature the follow-
ing clinical characteristics: female gender, older age, the absence of 
a preceding infection or vaccination, insidious disease onset, and a 
relatively higher platelet count at diagnosis.10 A recent analysis in the 
Intercontinental Cooperative ITP Study Group (ICIS) Registry II also 
showed age and bleeding as potential predictors, but did not find 
effects of platelet count or sex, albeit with fewer observations than 
in the previous meta-analysis.11 Notably, these predictors correlate 
with each other, in particular with age (Schmidt et al; medRxiv pre-
print https://doi.org/10.1101/2020.06.09.20125385). Moreover, 
how well these characteristics actually predict ITP outcomes is not 
yet known (in terms of predictive ability, discrimination, calibration), 
as no multivariate clinical prediction models have been developed.
Clinical prediction models can assist clinicians to identify pa-
tients with a particular prognosis.12,13 In the case of childhood ITP, 
this concerns the identification of children that can be safely fol-
lowed by watchful waiting and minimal monitoring, and children 
with a high chance of persistent and chronic ITP. Importantly, the 
error rates and clinical utility of prediction models can be evaluated. 
Moreover, it can be evaluated how the extension of a model by fur-
ther clinical predictors or biomarkers can improve prediction.14 In 
2007, Edslev et al proposed a clinical prediction score for transient 
ITP, using insidious onset, age <10 years, a preceding infection, a 
platelet count <5 × 109L, the presence of wet purpura, and male 
sex.15 This simple Bayesian score has some drawbacks: individual-
ized risk estimates cannot be obtained, multivariate effects are not 
considered, and information on risk differentiation from continu-
ous variables is lost due to dichotomization.16 Moreover, this score 
has not been prospectively validated in an external cohort, but two 
retrospective studies indicated that patients with the highest risk 
scores showed more often transient disease courses.17,18
The objective of this study was to develop a novel clinical predic-
tion tool to predict transient versus persistent ITP disease courses in 
children with newly diagnosed ITP at the time of diagnosis. We used 
individual patient data of 577 patients from two large prospective 
childhood ITP studies.7,15 The data from the observational NOPHO 
(Nordic Pediatric Hematology-Oncology) ITP study were used to de-
velop the score. By validating the score in the TIKI (Treatment With 
or Without Intravenous Immunoglobulins in Kids with ITP) random-
ized trial, we were able to test the usefulness of the new score in pre-
dicting disease outcomes in untreated children, as well as children 
treated with intravenous immunoglobulins (IVIg).
2  | METHODS
2.1 | Study design, data sources, and ethical 
considerations
The study is reported according to the TRIPOD (transparent report-
ing of a multivariate prediction model for individual prognosis or 
diagnosis) checklist for prediction model development and valida-
tion.19 Two cohorts were included in this study to develop and vali-
date the clinical prediction model. The NOPHO ITP study included 
children with newly diagnosed ITP in a prospective registry cohort 
in five Nordic countries between 1998 to 2000.5,15 Patients with 
a diagnosis of ITP consistent with clinical criteria and absent clini-
cal or laboratory evidence of alternative causes for thrombocyto-
penia were recruited at pediatric departments. Data was recorded 
at diagnosis. Children with an age below 15 years and a platelet 
count ≤20 × 109/L and available 6-month follow-up were included 
(Figure 1A; N = 377). The study was approved by ethical review com-
mittees and authorities in each participating country. A second co-
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Essentials
• There is a need for improved tools to predict persistent 
and chronic immune thrombocytopenia (ITP).
• We developed and validated a clinical prediction model 
for recovery from newly diagnosed ITP.
• The Childhood ITP Recovery Score predicts tran-
sient vs. persistent ITP and response to intravenous 
immunoglobulins.
• The score may serve as a useful tool for clinicians to in-
dividualize patient care.
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trial,7 a multicenter randomized controlled trial in the Netherlands 
that enrolled children between 2009 and 2015 (Figure 1B; N = 194). 
Inclusion criteria were an age between 3 months and 16 years and a 
platelet count ≤20 × 109/L. Patients were excluded when severe or 
life-threatening bleeding was present (Buchanan score ≥ 4), immu-
nomodulatory drugs were given within 1 month of diagnosis, or con-
traindications to IVIg therapy were present. Clinical characteristics 
were obtained at diagnosis and registered in standardized clinical re-
port forms. Enrolled patients were randomized to receive careful ob-
servation or a single dose of 0.8g/kg IVIg. During follow-up, patients 
were routinely assessed according to a pre-defined schedule at 1 
and 4 weeks, as well as 3, 6, and 12 months after the diagnosis. The 
study was approved by the Institutional Review Board of University 
Medical Center Utrecht. Patients (≥12 years) and parents gave writ-
ten informed for study participation. All analyses were performed on 
deidentified, coded data. Of note, in both studies, patients were not 
eligible for participation when there were indications for other un-
derlying conditions (secondary ITP) from the patient history, physical 
exam, or laboratory tests.
2.2 | Clinical outcome definitions
Recovery was assessed at each follow-up, according to standardized 
outcome criteria by the International Working Group.20 Complete 
recovery was defined as a platelet count ≥100 × 109/L. Transient 
ITP was defined as a complete recovery 3 months after diagnosis. 
In the NOPHO study, transient ITP was defined as a platelet count 
≥150 × 109/L 3 months after diagnosis. Persistent ITP was defined 
as the absence of transient ITP,20 and includes here both children 
with recovery after 3 months and with disease lasting for more than 
1 year.
F I G U R E  1   Flow chart of included study cohorts. A, from the NOPHO ITP study and B, TIKI trial.
Registered with newly diagnosed ITP
in NOPHO ITP study (N = 506)
Platelet count <30 x 109/L 
but >20 x 109/L (N = 32)
Incomplete follow-up  
at six months (N = 97)
Final study population (N = 377)
Registered with newly diagnosed ITP
in TIKI trial (N = 206)
Excluded (N = 6)
- Declined to participate
- Not meeting inclusion criteria
Randomized (N = 200)
Observation (N = 100)IVIg (N = 100)
Final study population (N = 194)
Missing data (N = 4)Missing data (N = 2)
A
B
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Rescue treatment with corticosteroids or IVIg between 1 and 
3 months after the diagnosis was administered to three patients 
(NOPHO) and seven patients (TIKI). A further eleven patients of the 
NOPHO study received rescue treatment, but no exact date was re-
corded. Following rescue treatment, one patient of the TIKI study 
and none in the NOPHO study exhibited a complete recovery at the 
time of assessment of the clinical outcome.
2.3 | Predictor definitions
The following predictors were included: age (continuous, years), 
sex (male/female), self-reported history of a preceding infection or 
preceding vaccination within 28 days (TIKI) or 1 month (NOPHO) of 
diagnosis (two variables, dichotomous), insidious disease onset (self-
reported symptom duration ≥14 days), and platelet count at the time 
of diagnosis (continuous, ×109/L). Mucosal bleeding was defined as 
presence of “wet purpura/mucosal oozing” (NOPHO ITP study) or a 
modified Buchanan score ≥ 3 (TIKI study).5,7,21 A linear effect term 
in the prediction model was judged to sufficiently approximate the 
association of age and platelet count with the probability of transient 
ITP (Figure S1 in supporting information).
2.4 | Model development
The model was developed in the NOPHO ITP study. To predict tran-
sient versus persistent ITP, a binomial logistic regression model was 
fitted with ridge regression using glmnet.22,23 Ridge regression is 
a preferred shrinkage technique when variable selection is not re-
quired.24 Ridge regression also deals well with collinearity of predic-
tors and prevents overfitting.25-27 All considered clinical predictors 
on which data was collected (see above) were included in the final 
model, irrespective of their predictive ability, as ridge regression 
shrinks effects toward zero for irrelevant predictors, and there is no 
cost in obtaining the parameters clinically. The optimal shrinkage pa-
rameter was determined by 10-fold cross-validation.
2.5 | Model validation and performance
The prediction model was validated in the study population of the 
TIKI trial. Discriminative ability was assessed by the receiver operating 
characteristic (ROC) area under the curve. Calibration was evaluated 
by calculating mean predicted and observed proportions of complete 
recovery 3 months after diagnosis (ie, transient versus persistent ITP).
2.6 | Statistical analyses
Statistical analyses were performed in R (version 3.6.0). No sample 
size calculation was performed. Six patients from the TIKI trial were 
excluded because of a missing clinical characteristic; data were not 
imputed. Penalized regression reduces the variance of regression esti-
mators; confidence intervals are therefore not displayed.28 Longitudinal 
recovery rates (first complete recovery) were visualized with Kaplan-
Meier curves. Effects of the score on recovery were quantified with a 
Cox proportional hazard model with the score as a continuous predic-
tor. Effect estimates obtained during the model validation are unbiased 
due to the independent development and validation steps.
3  | RESULTS
3.1 | Baseline characteristics and incidence of 
transient ITP in NOPHO and TIKI cohorts
The final study population included 571 patients for model de-
velopment and validation (Figure 1). In the NOPHO ITP study, 
the outcome was missing in 97/506 (19%) of patients. The clinical 
characteristics of both study cohorts were similar at the diagnosis 
(Table 1). Moreover, the pre-test probability of a favorable disease 
outcome, ie, the incidence of transient ITP 3 months after diagnosis, 
was also similar (68% and 73% for NOPHO and TIKI, respectively; 
Table 1). Thus, despite differences in the geographical location and 
the inclusion period and the exclusion of severe bleeding patients 
in the TIKI trial, the patient characteristics were homogeneous be-
tween the cohorts.
3.2 | Development of the Childhood ITP Recovery 
Score for transient ITP
For model development (Figure 2A), 255 events of transient ITP 
were predicted in 377 patients, using clinical characteristics 
TA B L E  1   Baseline characteristics of patients with ITP in the 
development and validation cohort
Development 
(NOPHO) N = 377
Validation 
(TIKI) N = 194
Age, median (IQR) 4.0 (2.0; 7.0) 4.0 (2.4; 7.5)
Platelet count, ×109/L, 
median (IQR)
7 (4; 12) 6 (3; 10)
Female 162 (43%) 88 (45%)
Preceding infection 217 (58%) 108 (56%)
Preceding vaccination 27 (7%) 7 (4%)
Mucosal bleeding 165 (44%) 79 (41%)
Insidious disease onset 84 (22%) 28 (15%)
Transient ITP (3 months) 255 (68%) 142 (73%)
Note: Data are N (% of cohort) unless stated otherwise. Preceding 
infection was defined ≤1 month prior to onset of disease. Insidious 
disease onset, symptoms ≥14 days at diagnosis.
Abbreviations: IQR, interquartile range; ITP, immune thrombocytopenia; 
NOPHO, Nordic Pediatric Hematology-Oncology ITP study; TIKI, 
Treatment With or Without Intravenous Immunoglobulins in Kids with 
ITP trial.
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obtained at the diagnosis. A penalized regression model was 
fit to predict transient versus persistent ITP at 3 months fol-
low-up (Figure 2B). The association of the absence of an insidi-
ous disease onset with transient ITP was the most pronounced 
of all predictors. Coefficients of the model (the Childhood ITP 
Recovery Score) are given in Table 2. The predicted probabili-
ties obtained from the model were similarly distributed between 
the NOPHO and TIKI cohorts with an approximate bimodal pat-
tern (Figure 2C). In particular, we observed a large proportion 
of patients with transient ITP who exhibited scores above ~0.5, 
corresponding to a ~62% posterior probability (the predicted 
probability by the model to have transient ITP after considera-
tion of all predictors). Compared to the NOPHO ITP score,15 the 
Childhood ITP Recovery Score showed additional differentiation 
in patients with intermediate NOPHO scores between 4 and 12, 
and overall a good correlation (Spearman rho 0.82; P < .0001). 
The Childhood ITP Recovery Score is available as an online calcu-
lator (http://www.itpre cover yscore.org); an example calculation 
of the score “by hand” is given in Appendix S1 in the Supporting 
Information.
3.3 | Model performance and validation of the 
childhood ITP recovery score in the TIKI cohort
The transient and persistent ITP disease courses were discrimi-
nated with a receiver operating characteristic area under the curve 
(ROC AUC) of 0.70 (95% confidence interval [CI], 0.65-0.74) in the 
NOPHO evaluation and 0.71 (95% CI, 0.62-0.80) in the TIKI external 
validation (Figure 2D). A ROC AUC of 0.50 indicates random clas-
sification of the patients, and 1.00 perfect classification. In the TIKI 
cohort we observed an equal discrimination of disease courses in 
patients randomized to careful observation (ROC AUC 0.71, 95% CI 
0.58-0.83) and IVIg treatment (ROC AUC 0.69, 95% CI 0.54-0.85). 
The assessment of the model calibration showed a clear relationship 
between predicted and observed probabilities of complete recovery 
F I G U R E  2   Development of the Childhood ITP Recovery Score and discrimination of disease courses. A, The score was developed in the 
NOPHO (Nordic Pediatric Hematology-Oncology) ITPstudyby multivariate penalized logistic regression and evaluated in the TIKI (Treatment 
With or Without Intravenous Immunoglobulins in Kids with ITP) randomized controlled trial. B, Ridge regression coefficients (each line is one 
predictor), based on different penalty factors (lambda). The optimal lambda value (dashed line) was chosen by 10-fold cross-validation using 
binomial deviance. The largest coefficient was observed for insidious disease onset. C, Linear predictor of the Childhood ITP Recovery Score 
for transient versus persistent ITP disease courses in the derivation and external validation cohorts NOPHO and TIKI, respectively. A similar 
score distribution is observed. D, Receiver-operating characteristic area under the curve for the Childhood ITP Recovery Score. A similar 
discrimination is observed between the derivation and external validation cohort, illustrating the robust generalizability of the Childhood ITP 
Recovery Score, as developed with penalized regression.
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(Figure 3A-B). Furthermore, the calibration was similar in the devel-
opment and validation cohorts.
3.4 | Differentiation of disease courses during long-
term follow-up and after IVIg treatment
The Childhood ITP Recovery Score also differentiated the com-
plete recovery rates at 6- and 12-months follow-up, with compa-
rable rates between both cohorts (Table 3). Using data from the 
TIKI trial, we also assessed the predictive ability of the Childhood 
ITP Recovery Score for longitudinal disease courses during 1-year 
follow-up, both for patients randomized to observation or IVIg treat-
ment. Inspecting Kaplan-Meier curves for three terciles of scores, 
the group with the lowest Childhood ITP Recovery Score was clearly 
associated with a reduced chance for complete recovery during 
follow-up, and included a high proportion of patients with chronic 
ITP 1 year after diagnosis (Figure 4). Notably, we focused on a first 
observed recovery, whereas a small proportion of children showed 
recurrent thrombocytopenia with platelets below 30 × 109/L after 
this: two patients in the observation cohort and six in the IVIg cohort 
(Figure S3 in Supporting Information). The spontaneous recovery in 
untreated patients and responses to IVIg were similarly associated 
with the Childhood ITP Recovery Score (Figure 4), where the group 
of patients with the lowest scores showed enrichment of persistent 
and chronic ITP disease courses. Of note, the administration of IVIg 
treatment to patients with the lowest scores still resulted in a 50% 
response rate to IVIg (Figure 4B). During the full 1-year follow-up, 
an increase of one unit in the Childhood ITP Recovery Score corre-
sponded with a hazard ratio for complete recovery of 2.59 (95% CI, 
1.66-4.04) in the observation cohort and 1.56 (95% CI, 1.01-2.42) 
in the IVIg cohort, where a hazard ratio of 1.00 would indicate no 
difference in recovery. The Childhood ITP Recovery Score also cor-
related with bleeding symptoms as assessed by the Buchanan score 
throughout follow-up (Table 4).
3.5 | Clinical scenarios
To illustrate the use of the prediction model to derive post-test prob-
abilities, we first consider the case of a boy with a diagnosis platelet 
count of 8 × 109/L, a preceding infection, no vaccination history, mu-
cosal bleeding, and an abrupt disease onset. At the age of 2, 8, and 
14 years, the Childhood ITP Recovery Score gives a probability for 
TA B L E  2   Regression coefficients and odds ratios of the 
association between the predictors and the occurrence of transient 
versus prolonged ITP disease courses
Coefficient Odds ratio
Intercept 1.11
Age, per year −0.03 0.97
Platelet count, ×109/L (steps of 1) −0.02 0.98
Male 0.09 1.10
Preceding infection 0.18 1.20
Preceding vaccination 0.11 1.12
Mucosal bleeding 0.17 1.18
Insidious disease onset −1.15 0.32
Note: Variables are for presence (categorical variable) with the usual 
dummy coding (0, absence; 1, presence) or a one-unit increase 
(continuous variable) of the respective predictor. Coefficients are for 
the linear predictor for logit (transient ITP). The odds ratio is given for 
transient ITP. Confidence intervals or p-values are not obtained for 
penalized regression (see Methods).
Abbreviation: ITP, immune thrombocytopenia.
F I G U R E  3   Calibration of the Childhood ITP Recovery Score. Data are shown for A, the development cohort (NOPHO [Nordic Pediatric 
Hematology-Oncology]) and B,the external validation cohort (TIKI [Treatment With or Without Intravenous Immunoglobulins in Kids with 
ITs]). Probabilities were grouped in deciles. Points represent mean ± standard error. Solid line, ideal fit; dashed line, linear fit of observed 
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transient ITP of 79%, 76%, and 73% (all grouped as “high”), respec-
tively. Thus, age marginally impacted the boy's chance for recovery, 
and the score suggests that the child will have a high chance of a 
transient disease course.
Next we consider the case of a girl of 4 years of age. She has a diag-
nosis platelet count of 8 x 109/L, no history of a preceding infection or 
vaccination, and skin bleeding only, and an insidious disease onset. The 
Childhood ITP Recovery Score probability for transient ITP is 42%. If 
the girl was 14 years instead, the probability of recovery would be 35% 
(both “low”). The presence of a preceding infection, for the two ages, 
would adjust the probability to 47% and 39% (both “low”), respectively. 
Thus, one might consider anticipating a longer duration of disease with 
more morbidity, irrespective of age and a preceding infection.
Together, these cases display how the use of the presented clin-
ical prediction score allows evidence-based weighing of complex 
clinical characteristics.
4  | DISCUSSION
In the present study, we have developed and externally validated 
a clinical prediction score to determine course of disease in newly 
diagnosed childhood ITP. All predictors are easily available at di-
agnosis. The score is developed in the NOPHO cohort and exter-
nally validated in the TIKI trial, and shows differentiation of disease 
courses and bleeding symptoms, both for patients randomized to 




High chance of 
recovery
NOPHO (N = 377)
N (% of total) 84 (22%) 70 (19%) 223 (59%)
Month 3 0.37 (0.27-0.47) 0.64 (0.53-0.76) 0.80 (0.75-0.85)
Month 6 0.45 (0.35-0.56) 0.73 (0.62-0.83) 0.87 (0.82-0.91)
Chronic ITP (old definition) 0.55 0.27 0.13
TIKI (N = 194)
N (% of total) 28 (14%) 45 (23%) 121 (63%)
Month 3 0.32 (0.15-0.49) 0.69 (0.55-0.82) 0.85 (0.79-0.91)
Month 6 0.46 (0.28-0.65) 0.82 (0.71-0.93) 0.90 (0.85-0.95)
Chronic ITP (old definition) 0.54 0.18 0.10
Month 12 0.71 (0.55-0.88) 0.87 (0.77-0.97) 0.95 (0.91-0.99)
Chronic ITP 0.29 0.13 0.05
Note: Data are the proportion (95% CI) of patients experiencing a complete recovery at the 
indicated timepoint. The definition of chronic ITP was changed in 2009 from ITP lasting more than 
6 months after the diagnosis to 12 months after the diagnosis.20
Abbreviations: CI, confidence interval; ITP, immune thrombocytopenia; NOPHO, Nordic Pediatric 
Hematology-Oncology ITP study; TIKI, Treatment With or Without Intravenous Immunoglobulins 
in Kids with ITP trial.
TA B L E  3   Proportion of patients from 
the NOPHO ITP study and TIKI trial who 
exhibited complete recovery or chronic 
ITP during 1-year follow-up, according 
to the Childhood ITP Recovery Score 
prediction of the chance of recovery at 
3-month follow-up. The score was split as 
outlined in the main text
F I G U R E  4   Longitudinal recovery 
from immune thrombocytopenia (ITP) 
based on the Childhood ITP Recovery 
Score. Differentiation of disease courses 
in the TIKI (Treatment With or Without 
Intravenous Immunoglobulins in Kids 
with ITP) trial for patients randomized to 
the (A) observation and (B) intravenous 
immunoglobulin (IVIg) cohort. A first 
complete recovery is considered as event. 
Statistics are given for a log-rank test 
for the null hypothesis that differences 
in complete recovery in all three groups 
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Log-rank, P = 0.05Log-rank, P<0.0001
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128  |     SCHMIDT eT al.
careful observation as well as treatment with IVIg. Thus, the clini-
cal parameters included in the Childhood ITP Recovery Score are 
associated with ITP disease courses, irrespective of treatment. The 
cohorts were independent with regard to time and geography. The 
Childhood ITP Recovery Score is available as an online calculator 
that provides an individualized probability for transient ITP (http://
www.itpre cover yscore.org).
4.1 | Strengths and limitations
Our study combines two large European prospective multicenter 
studies conducted in childhood ITP to date, providing a relatively 
large sample size for a study in a rare disease. A major strength 
is that these cohorts were independent with regard to time and 
geography. Moreover, the Nordic and Dutch study populations 
showed similar clinical characteristics and disease outcomes. The 
key improvements over the previously introduced score by Edslev 
et al15 are the development of a multivariate score, the larger 
derivation cohort, and the integration of additional information 
by inclusion of previously dichotomized predictors as continuous 
variables.16 Multivariate ridge regression does not require removal 
of predictors, and there is no clinical cost to obtaining any of the 
included variables. Statistically, the similar ROC AUC between 
the development and validation cohort illustrates the strength of 
ridge regression for shrinkage of coefficients by cross-validation, 
thereby preventing overfitting.
An initial concern for our study was that 19% of the patients in-
cluded in our development cohort5 did not have baseline and fol-
low-up data available, which might have been due to selective loss to 
follow-up. Although we cannot exclude this possibility, we were re-
assured by the similar clinical characteristics and disease outcomes 
between the NOPHO and TIKI population. Moreover, the external 
validation of the prediction model in the TIKI trial showed robust 
results. The generalizability of our study is limited to the inclusion 
criteria, ie, children between 6 months and 16 years of age and a 
diagnosis platelet count below 20 × 109/L. Because the NOPHO ITP 
study defined the outcome at 150 × 109/L, instead of 100 × 109/L in 
TIKI, the NOPHO recovery frequency was marginally lower during 
follow-up. Another limitation is that we did not fit interaction ef-
fects in the prediction model, but this may be considered with larger 
available sample sizes (eg, age, sex). It is unlikely that the inclusion of 
mucosal bleeding in the prediction model had a large effect on our 
score's relationship with bleeding during follow-up, because in the 
TIKI cohort, bleeding symptoms at the diagnosis alone do not pre-
dict bleeding during follow-up well (data not shown), and the effect 
size of bleeding in our multivariate prediction model is small. The 
self-reporting of the symptom duration (disease onset) and a pre-
ceding infection implies potential recall bias. However, this was no 
strict limitation for the aim of prediction, and we observed that such 
self-reported variables obtained in routine clinical care can be good 
predictors of disease courses.
4.2 | Findings of others
We have previously systematically reviewed clinical and laboratory 
predictors of chronic ITP.10 Most of the included studies in this sys-
tematic review only assessed a single or small selection of predictors 
and incompletely reported other data. Clearly, some predictors of 
disease courses may correlate (eg, a low platelet count and more se-
vere bleeding symptoms; female sex and an older age at diagnosis), 
yet multivariate analyses have rarely been performed. Moreover, it 
remained unclear whether the findings of small studies are gener-
alizable to other populations. The multivariate effect sizes included 
in the presented prediction model require careful comparison to 
historical data, given the penalization effects in ridge regression. 
However, even when no penalty was subjected to the regression 
coefficients (λ → 0; Figure 2), the variables gender, the presence of 
a preceding infection or vaccination, an insidious disease onset, and 
mucosal bleeding all had significantly reduced effect sizes,10 as may 
be expected from a multivariate model. An important consideration 
is that these predictors, except for bleeding, are strongly associated 
with age at presentation (Schmidt et al; medRxiv pre-print https://
doi.org/10.1101/2020.06.09.20125385). Overall, the most impor-
tant predictor for transient ITP was the absence of an insidious dis-
ease onset, which is in line with the very large effect size identified 
in our systematic review (odds ratio for chronic ITP, 11.3 [95% CI, 
TA B L E  4   Proportion of patients in the TIKI trial with bleeding 
events during 1-year follow-up, stratified by the Childhood ITP 











At least extensive petechiae and/or large bruises (Buchanan 
score > 1)
Week 1 0.75 ± 0.08 0.87 ± 0.05 0.62 ± 0.05
Month 1 0.79 ± 0.08 0.58 ± 0.07 0.41 ± 0.05
Month 3 0.75 ± 0.08 0.42 ± 0.08 0.29 ± 0.04
Month 6 0.69 ± 0.09 0.51 ± 0.08 0.33 ± 0.05
Month 
12
0.45 ± 0.11 0.20 ± 0.06 0.15 ± 0.04
At least mucosal bleeding (Buchanan score > 2)
Week 1 0.43 ± 0.09 0.49 ± 0.07 0.33 ± 0.04
Month 1 0.50 ± 0.09 0.18 ± 0.06 0.22 ± 0.04
Month 3 0.36 ± 0.09 0.19 ± 0.06 0.10 ± 0.03
Month 6 0.27 ± 0.09 0.10 ± 0.05 0.08 ± 0.03
Month 
12
0.14 ± 0.07 0.08 ± 0.04 0.04 ± 0.09
Note: Observed proportion of patients ± standard error. Data are the 
proportion of patients experiencing the indicated modified Buchanan 
score at the indicated follow-up timepoint.
Abbreviations: ITP, immune thrombocytopenia; TIKI, Treatment With or 
Without Intravenous Immunoglobulins in Kids with ITP.
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6.3-20.3]10). Of note, the dichotomization of continuous variables 
may lead to type I errors and produce inflated effect sizes;16,29 this 
was prevented in our model development by the inclusion of age 
and platelet count as continuous variables. The effect of age was 
lower than in previous publications,10 as we also display in the clini-
cal scenarios, and this may be related to our adjustment for mul-
tivariate effects and penalization, as well as the dichotomization 
of age in previous studies. Overall, our study underscores that the 
unadjusted effect sizes of some prior studies should be interpreted 
with caution.
4.3 | Clinical implications
A key clinical challenge in childhood ITP is the early identification 
of a patient's disease course to counsel families; inform treatment 
decisions; and guide additional diagnostics, eg, screening for sys-
temic autoimmune diseases, immunodeficiencies, or genetic throm-
bocytopenia. Clinical parameters for our model are readily available 
and there is no cost involved in obtaining them. We suggest that 
the Childhood ITP Recovery Score allows the targeting of inten-
sive monitoring or additional diagnostic efforts to children with low 
probability of recovery. On the other hand, in children with high 
probability of recovery, the rate for persistent and chronic ITP is low 
and they could be monitored “hands-off,” if this is clinically judged 
to be possible. In addition, in these children with a high probability 
of recovery, emergency treatment with IVIg, or treatment aiming to 
resolve thrombocytopenia, is likely to be effective. The clinical util-
ity of the score may be assessed in a clinical impact study. The score 
may also be used for stratification of additional laboratory testing, 
eg 1 or 3 months after the diagnosis, which may give further infor-
mation for the ITP prognosis.
There remains a need for research to investigate the integration 
of additional clinical data as well as molecular information (eg, an-
ti-platelet antibodies, T and B cell markers; related to pathogenesis 
of ITP) to further improve the prediction of disease courses and re-
sponse to therapy in newly diagnosed ITP.
5  | CONCLUSIONS
The Childhood ITP Recovery Score could be clinically useful to dif-
ferentiate transient versus persistent disease courses in newly diag-
nosed childhood ITP, using clinical variables that are readily available 
at diagnosis.
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